A medicine for the treatment of prostate cancer has been registered in the Russian Federation
09:46, 27 December
The Federal Medical and Biological Agency (FMBA) has received a registration certificate for the import-substituted radiopharmaceutical «Racurs (223Ra)» for prostate cancer treatment. The information is announced in the Telegram channel of the Federal Medical and Biological Agency.
- Share on Facebook
- Share on VK
- Share on Twitter
«Russian medicine for prostate cancer treatment: import-substituted radiopharmaceutical «Racurs (223Ra)» has been registered», says in the statement.
The medicine has been developed on the basis of domestic raw materials, it has a double effect.
«Firstly, it destroys metastases in the bones, giving an opportunity to a patient with a diagnosis of prostate cancer to prolong his life with the disease background. The medicine selectively accumulates in the bones, including bone metastases. The result of such treatment is a highly localised anti-tumour effect. Secondly, radium-223 affects the pain syndrome and gives the opportunity to refuse the use of analgesic drug therapy, thus significantly improves the quality of life of the patient», says in the statement.
